Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Win, Lose Or Yawn: Is Industry’s DTC Policy Working?

Executive Summary

Despite a strategic shift by industry curtailing playful ads and promotions in favor of a more serious clinical approach, the omission of risk information in advertising remains a pressing problem, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams said

You may also be interested in...



AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall

An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information

AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall

An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information

Risk/Benefit “Fair Balance” In DTC Ads Leads To Confusion – Petition

FDA should redefine its policy of requiring "fair balance" of risk and benefit information in prescription drug advertising, the Coalition for Healthcare Communication says in a March 31 citizen petition

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS046927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel